This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Low-Dose Risperidone and Quetiapine as Monotherapy for Comorbid Anxiety and Depression

Igor Galynker, MD, PhD; Asim Khan, MD; Yuli Grebchenko, MD; Aleksey Ten, MD; Liliya Malaya, PhD; Philip Yanowitch, MD; and Lisa J. Cohen, PhD

Published: April 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Up to 80% of patients with generalized anxiety disorder(GAD) suffer from a comorbid mood disorder.1 Atypical antipsychoticsare frequently prescribed as off-label adjunctivetreatment for GAD and major depressive disorder (MDD); however,no studies have demonstrated the effectiveness of thesedrugs as monotherapy.2,3 Here, we present a case series describingthe use of risperidone and quetiapine as monotherapy forGAD and MDD.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: Dementia , Neurologic and Neurocognitive

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...